Clinical Research Directory
Browse clinical research sites, groups, and studies.
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Sponsor: West China Second University Hospital
Summary
Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.
Official title: Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma
Key Details
Gender
FEMALE
Age Range
Any - 40 Years
Study Type
INTERVENTIONAL
Enrollment
224
Start Date
2018-04-01
Completion Date
2030-12-30
Last Updated
2021-09-13
Healthy Volunteers
No
Interventions
Progesterone
MPA oral 250mg-500mg qd for 3 months per cycle
Mirena®
levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
GnRH agonist
GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
Locations (1)
West China Second University Hospital
Chengdu, Sichuan, China